Leerink Partners cuts Veracyte to Market Perform from Outperform, target to $35 from $55
VCYT•Leerink Partners cut its rating on Veracyte to Market Perform from Outperform and lowered its target price to $35 from $55.
Related News
Matson Inc: Stephens raises target price to $300 from $270
MATX•
Sezzle Inc: Needham raises target price to $220 from $172
SEZL•
Privia Health Q3 revenue beats estimates
PRVA•
V.F. Corporation: Barclays raises target price to $28 from $24
VFC•
Bernstein raises Zimmer Biomet target price to $107 from $93
ZBH•